COVID-19 Delta Variant: Implications for employers and the return to work WHITE PAPER - CVS Health
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
The SARS-CoV-2 mutation that now plagues the world is the B.1.617.2 variant, known as the Delta variant. The Delta variant has spread through many countries and is now the dominant variety of COVID-19 virus in the United States. As of July 20, the Delta variant represented 83 percent of new infections and will likely be almost 100 percent in a week or two.* This prevalence is likely to have implications for employers’ return-to-work plans this fall. Epidemiology and clinical impact The Delta variant is a model of viral mutation — different small changes in the molecular structure1 that occur as a result of random variation and create selection pressure for more “successful” models. It is 60 percent more transmissible than the previously dominant Alpha variant, which in turn was at least 60 percent more transmissible than the original SARS-CoV-2 strain. The “load” of virus, or the number of copies a person harbors early in infection, is likely at least 1,000 times greater than the amount harbored by those originally infected with SARS-CoV-2.2 In very real terms, whereas the original SARS-CoV-2 strain carrier would infect 2.5 people, the Delta carrier likely infects up to 6 people.3 Not only more transmissible, Delta is also considered more virulent, in that it causes worse disease. A study in Scotland suggested that people infected with Delta were 85 percent more likely to be hospitalized than people infected with Alpha.4 The mortality differences are not yet known, but public officials are very worried. The Delta variant is now the dominant variety of COVID-19 virus in the United States. CVS Health: Perspectives on the COVID-19 Delta Variant | 2
COVID-19 rates of transmission SARS-CoV-2 3 COVID-19 Delta variant 83 % of new 1 2.5 infections person people Delta variant 60% more transmissible 1,000x viral load 1 up to 6 person people CVS Health: Perspectives on the COVID-19 Delta Variant | 3
The role of vaccinations The key solution to this phase of the pandemic is vaccination, preferably with messenger RNA (mRNA) vaccines. Many of those who are vaccinated will be able to completely resist the virus and, if vaccinated people do become infected, they are unlikely to get sick or be hospitalized.5 Moreover, vaccinated individuals will have much lower viral loads and represent less risk to others. Those who remain unvaccinated face substantial risk of severe illness and will contribute significantly to ongoing spread of the virus. There is also evidence that Delta may be more likely to evade some vaccine protection. While original reports6 suggested that protection from the Johnson & Johnson (J&J) vaccine was similar for Alpha and Delta, results emerged on July 20 that seem to suggest the J&J vaccine is less protective against Delta.7 The mRNA vaccines from Pfizer and Moderna appear to guard against hospitalization and severe infection, but more viral-positive, previously vaccinated people with mild disease are being reported — and they likely can infect others. COVID-19 cases across the United States have significantly increased since early June and continue to trend upward, especially in areas with lower vaccination rates. CVS Health: Perspectives on the COVID-19 Delta Variant | 4
Viral density of the Delta variant Perhaps the easiest way to look at this is to think about viral density. Vaccination in any metropolitan area decreases viral density. Towns and cities with high vaccination rates have much lower rates of virus present. But metropolitan areas that have low rates of vaccination have much higher rates of virus present, and even vaccinated people are at risk for infection. Unvaccinated people are at risk for serious illness and death. Further, unvaccinated people who have early infections with the Delta variant give off a dense fog of virus, compared to the wisps of virus observed in March of 2020 with the original SARS-CoV-2 strain. As a result, in a city with a low vaccination rate, a carrier of the Delta variant who goes indoors to an office or a restaurant puts everyone there at risk. Unvaccinated people By contrast, people who have early infected with the infections with the original SARS-CoV-2 Delta variant give off strain gave off wisps a dense fog of virus. of virus. CVS Health: Perspectives on the COVID-19 Delta Variant | 5
Testing trends Our recent epidemiological analyses demonstrate this case. Figure 1 illustrates that rates of positive tests are rising dramatically. Despite the hopes shared by many in early summer that the pandemic would fade away, it is back — and unfortunately there is a chance that an even more infectious mutant could replace the Delta variant. Figure 1 Total US incremental testing and case trends 2.4M 22 2.2M 20 2M 18 1.8M 16 7-day Percent Positivity 1.6M 14 Tests Reported 1.4M 12 1.2M 10 1M 8 800K 6 600K 400K 4 200K 2 0 0 Jan 22, ‘20 Apr 22, ‘20 Jul 22, ‘20 Oct 21, ‘20 Jan 20, ‘21 Apr 21, ‘21 Jul 23, ‘21 Reported US Tests % Positivity Source: View from CDC updated as of Jul 23, 2021 7 % Testing positivity has explosively increased to almost CVS Health: Perspectives on the COVID-19 Delta Variant | 6
COVID-19 is back, COVID-19 Hospitalization Trends Current State vs. June 6, 2021 especially in areas with low Avg. Daily COVID-19 vaccination rates Beds Used Last 7 Days % Change vs. 7 Days Vaccination State per 1 M Pop. Ending 7/24 Rate Figure 2 compares rates of known Nevada 323 +327% 53% infection in various states for June 6 with rates today. In Missouri Florida 273 +163% 57% and Arkansas, for example, rates of infection have risen eight-fold, Missouri 272 +150% 48% with overall low rates of protected individuals. With this rise in infections Arkansas 267 +259% 45% is a concomitant increase in Louisiana 183 +188% 41% hospitalization rates, as shown in Figure 3. Mississippi 154 +147% 39% Based on what we know, the Alabama 143 +94% 42% worst-case scenario is not being Texas 141 +97% 51% played out today, but could be a few weeks from now if the Delta Oklahoma 139 +138% 47% variant spreads unobstructed in an unvaccinated population. Kansas 127 +190% 53% Georgia 118 +51% 45% Ultimately, this kind of biological phenomenon can eventually help Arizona 117 +60% 52% overwhelm vaccine opposition. Wyoming 116 +51% 41% As Figure 4 shows, rates of new Alaska 104 +255% 51% vaccinations in Arkansas this week are more than double those in Kentucky 95 +33% 51% Massachusetts. In addition, those who survive infection will have some immunity which, like vaccination, protects the rest of the population. States with the 15 highest The overall pace of hospitalization rates vaccinations is still slow all have vaccination rates below 57%** despite cases significantly surging nationwide. CVS Health: Perspectives on the COVID-19 Delta Variant | 7
Implications for businesses For businesses across the country, the Delta variant will force us to redraw the map of how to return to the workplace. In the optimistic days of early June, going back to work and life as normal in the fall seemed guaranteed; we now see that it is not. Vaccination requirements For those who want to return to “normal” work, a reasonable option for employers to consider from a clinical perspective is to allow only vaccinated individuals to enter the workplace. Those who have not been vaccinated may increasingly be asked to work remotely, or, perhaps in highly vaccinated areas, be allowed to return to the worksite only with full-time N-95 mask coverage. As the Delta variant progresses, employers may wish to consider recommending N-95 masks even for vaccinated colleagues. Otherwise, there is the risk that the unvaccinated could infect even some of those who are vaccinated, who in turn can infect others, especially children who are not yet qualified for vaccination. Periodic testing More frequent testing will also be necessary. Low-cost, very accurate tests are available today that can detect the Delta variant and ongoing viral mutations. In some cases, employers may decide that everyone coming into the workplace should be tested periodically. Mask mandates As we approach inclement weather that drives people inside, we will likely see another upswing in infections. Masks indoors for all could very well be the default approach by year-end, as we try to get to a more completely immune population, which would eventually decrease the overall viral density and the opportunity for the virus to mutate toward more infectious variants. It is not a pretty picture, but prudent employers should start to consider their next steps with these considerations in mind. CVS Health: Perspectives on the COVID-19 Delta Variant | 8
Looking ahead The Delta variant will spread widely in the coming weeks and months. Ideas that were once thought to be off the table, such as vaccine mandates for employees, may increasingly appear reasonable and necessary. Wider use of masks likely will return, as will testing. At the beginning of this pandemic, wise epidemiologists were unanimous that this would be a three- to four-year struggle, and they are appearing especially prescient. Hopefully, this reality will wear down vaccination hesitance and antipathy to public health, which would help us overcome this pattern of recurring upswings in viral prevalence. Businesses can help take the lead. Troy A. Brennan, MD Executive Vice President and Chief Medical Officer, CVS Health Sree Chaguturu, MD Senior Vice President, CVS Health and Chief Medical Officer, CVS Caremark Kyu Rhee Senior Vice President and Chief Medical Officer, Aetna CVS Health: Perspectives on the COVID-19 Delta Variant | 9
APPENDIX Back Figure 2 COVID-19 Case Trends Current State vs. June 6, 2021 State Avg. Daily Cases per 1M Pop. Avg. Daily Cases per 1M Pop., Avg7Daily (vs. Days Cases per 1M Ending Pop 6/6) 7 Days Ending 6/6 State (Vs 7 Days Ending 6/6) Avg Daily Cases per 1M Pop, 7 Days Ending 6/6 Arkansas 605 (+1080%) 51 Louisiana 519 (+636%) 71 Florida 487 (+507%) 80 Missouri 394 (+649%) 53 Mississippi 306 (+715%) 38 Alabama 305 (+380%) 64 Nevada 276 (+262%) 76 Alaska 269 (+428%) 51 Oklahoma 237 (+748%) 28 Kansas 187 (+423%) 36 Wyoming 180 (+50%) 119 Texas 178 (+272%) 48 Arizona 175 (+166%) 66 Utah 169 (+135%) 72 California 164 (+616%) 23 Georgia 158 (+364%) 34 Kentucky 151 (+122%) 68 Tennessee 149 (+394%) 30 Hawaii 142 (+280%) 37 South Carolina 140 (+385%) 29 North Carolina 123 (+158%) 48 Washington 116 (+47%) 79 Idaho 115 (+84%) 63 Puerto Rico 100 (+357%) 22 Oregon 97 (+44%) 67 Indiana 91 (+50%) 61 Illinois 90 (+123%) 40 New Mexico 88 (+99%) 44 Montana 79 (+31%) 60 New Jersey 77 (+170%) 28 Notes: 1. Historical values may have slightly changed since first reported due to retroactive reporting changes by states. 2. Top 30 states by cases / population are shown in the chart. 3. Data as of July 25, 2021. CVS Health: Perspectives on the COVID-19 Delta Variant | 10
APPENDIX Back Figure 3 COVID-19 Hospitalization Trends Current State vs. June 6, 2021 State Avg. Daily COVID-19 Beds Used Last Avg. Daily COVID-19 Beds Used Last 7 Days per 1M Pop. per 1M Pop., 7 Days Ending 6/6 (vs. 7 Days Avg Daily Ending COVID 6/6)Last 7 Days / 1M Pop Beds Used Avg Daily COVID Beds Used Last per 1M Pop, State (Vs 7 Days Ending 6/6) 7 Days Ending 6/6 Nevada 323 (+327%) 76 Florida 273 (+163%) 104 Missouri 272 (+150%) 109 Arkansas 267 (+259%) 74 Louisiana 183 (+188%) 63 Mississippi 154 (+147%) 62 Alabama 143 (+94%) 74 Texas 141 (+97%) 72 Oklahoma 139 (+138%) 59 Kansas 127 (+190%) 44 Georgia 118 (+51%) 78 Arizona 117 (+60%) 73 Wyoming 116 (+51%) 77 Alaska 104 (+255%) 29 Kentucky 95 (+33%) 71 Utah 94 (+119%) 43 Tennessee 87 (+22%) 72 Indiana 81 (-16%) 96 District of Columbia 76 (-54%) 164 Idaho 72 (+12%) 64 Washington 71 (-20%) 88 Colorado 70 (-19%) 86 California 69 (+105%) 34 North Carolina 69 (+21%) 57 Rhode Island 67 (-21%) 85 Montana 67 (+12%) 60 Iowa 66 (-1%) 67 Ohio 65 (-29%) 91 South Carolina 65 (+61%) 40 West Virginia 59 (-46%) 110 Notes: 1. Hospitalization data is updated weekly; data as of July 24, 2021. 2. Top 30 states by COVID-19 hospitalizations / population are shown in the chart. CVS Health: Perspectives on the COVID-19 Delta Variant | 11
APPENDIX Back Figure 4 Incremental Cases vs. State Vaccination Rates Average Daily New COVID-19 Cases by State Vaccination Active States Last Week Per 1M Population, 7 Days Ending 7/25/2021 (% Change vs. Prior 7 Days) ME ME 46 (↑68%) 0.49% AK 269 VT NH AK 29 26 0.42% VT NH (↑94%) 0.39% 0.49% (↑35%) (↑23%) WA MT ND MN WI MI NY MA RI 116 79 41 47 55 42 69 60 64 WA MT ND MN WI MI NY MA RI (↑24%) (↑40%) (↑45%) (↑52%) (↑84%) (↑74%) (↑51%) (↑102%) (↑97%) 0.64% 0.39% 0.52% 0.51% 0.54% 0.54% 0.81% 0.58% 0.69% ID WY SD IA IL IN OH PA NJ CT 115 180 32 63 90 91 61 42 77 55 ID WY SD IA IL IN OH PA NJ CT (↑40%) (↑31%) (↑75%) (↑114%) (↑79%) (↑38%) (↑76%) (↑85%) (↑67%) (↑93%) 0.43% 0.58% 0.73% 0.54% 0.78% 0.62% 0.47% 0.80% 0.89% 0.82% OR NV CO NE MO KY WV MD DE 97 276 74 72 394 151 61 41 60 OR NV CO NE MO KY WV MD DE (↑62%) (↑18%) (ϫ15%) (↑42%) (↑24%) (↑68%) (↑64%) (↑73%) (↑31%) 0.52% 1.10% 0.62% 0.83% 1.18% 0.80% 0.16% 0.77% 0.71% CA AZ UT KS AR TN VA NC 164 175 169 187 605 149 64 123 DC CA AZ UT KS AR TN VA NC 65 0.91% 0.69% 0.66% 0.77% 1.75% 0.76% 0.74% 0.79% DC (↑82%) (↑31%) (↑4%) (↑29%) (↑79%) (↑81%) (↑108%) (↑66%) 0.64% (↑63%) NM OK LA MS AL SC 88 237 519 306 305 140 NM OK LA MS AL SC (↑39%) (↑67%) (↑101%) (↑132%) (↑87%) (↑74%) 0.73% 0.85% 1.48% 1.06% 0.95% 0.75% TX GA 178 158 TX GA (↑50%) (↑78%) 1.15% 0.58% HI FL PR 142 487 100 HI FL PR (↑82%) (↑61%) (↑111%) 0.40% 1.34% 0.89% Daily Cases per 1M Population % 12+ Receiving First Dose Last Week 0 250 0.25% 1.00% Last Refresh Date: 07/25/2021 CVS Health: Perspectives on the COVID-19 Delta variant | 12
*COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University **COVID-19 Reported Patient Impact and Hospital Capacity by State Timeseries dataset, U.S. Department of Health and Human Services 1. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019- ncov%2Fcases-updates%2Fvariant-surveillance%2Fvariant-info.html. 2. https://www.medrxiv.org/content/10.1101/2021.07.07.21260122v1. 3. https://www.forbes.com/sites/williamhaseltine/2021/07/13/the-delta-dilemma-loosening-covid-19-controls-at-a-time-of-increased- danger/?sh=45471e222750. 4. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01358-1/fulltext. 5. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinated-people.html. 6. https://www.gov.uk/government/news/vaccines-highly-effective-against-b-1-617-2-variant-after-2-doses. 7. https://www.nytimes.com/2021/07/20/health/coronavirus-johnson-vaccine-delta.html. This page contains trademarks or registered trademarks of CVS Pharmacy, Inc. and/or one of its affiliates. ©2021 CVS Health. All rights reserved. 106-55365A 072721
You can also read